Stem cells in the treatment of Covid-19 acute respiratory syndrome: What do we know so far?
International Journal of Development Research
Stem cells in the treatment of Covid-19 acute respiratory syndrome: What do we know so far?
Received 08th September, 2020; Received in revised form 17th October, 2020; Accepted 19th November, 2020; Published online 31st December, 2020
Copyright © 2021, Lourenço, Othávio Denobe; Jassi, Fabrício Jose, Coléte, Juliana Zorzi; Foggiato, Augusto Alberto; Toledo Neto, João Lopes; Silva, Douglas Fernandes. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
According Stem cells are nonspecific cellular systems, found in different regions of the human body, which are characterized by self-renewal and differentiation into other specialized cell types. Mesenchymal stem cells have angiogenic, anti-apoptotic, immunomodulatory, anti-oxidant and anti-inflammatory properties, mainly due to the release of paracrine factors, which has enabled their study in several health processes, including lung damage. Its attributes help in modulating the immune response, decreasing inflammation and contributing to the endogenous pulmonary repair of patients affected by the acute respiratory distress syndrome, a process that can be identified in patients severely affected by COVID-19. Finally, the present review article concludes that the use of mesenchymal stem cells can act by reducing the phenomenon of cytokine storm, showing itself as a promising option for the treatment of several lung diseases, resulting from exacerbated inflammation, including infection by the pandemic virus SARS-CoV-2.
